Evidence map›Paper›PMID 31166977›Full record

ArticlePloS one2019

Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

A V Ramanan, L V Hampson, H Lythgoe, A P Jones, B Hardwick, H Hind, B Jacobs, D Vasileiou, I Wadsworth, N Ambrose and 11 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.International journal of environmental research and public health · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Chronic Nonbacterial Osteomyelitis in Children.Children (Basel, Switzerland) · 2021
    Review
  13. Prior Elicitation for Use in Clinical Trial Design and Analysis: A Literature Review.International journal of environmental research and public health · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 7 countries.

A V RamananPaediatric Rheumatology, Bristol Royal Hospital for Children, Bristol and Bristol Medical School, University of Bristol, Bristol, United Kingdom.
L V HampsonStatistical Methodology and Consulting, Novartis Pharma AG, Basel, Switzerland.
H LythgoeDepartment of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
A P JonesClinical Trials Research Centre, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.
B HardwickClinical Trials Research Centre, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.
H HindClinical Trials Research Centre, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.
B JacobsPaediatrics, Royal National Orthopaedic Hospital, London, United Kingdom.
D VasileiouDepartment of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, United Kingdom.
I WadsworthDepartment of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, United Kingdom.
N AmbroseRheumatology, University College Hospital, London, United Kingdom.
J DavidsonPaediatric Rheumatology, Royal Hospital for Children, Glasgow, United Kingdom.
P J FergusonStead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America.
T HerlinDepartment of Paediatrics, Aarhus University, Aarhus, Denmark.
A KavirayaniPaediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
O G KilleenNational Centre for Paediatric Rheumatology, Our Lady's Children Hospital, Crumlin, Dublin, Ireland.ORCID 0000-0001-5780-6468
S Compeyrot-LacassagneRheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
R M LaxerDepartment of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada.
M RoderickPaediatric Rheumatology, Bristol Royal Hospital for Children, Bristol and Bristol Medical School, University of Bristol, Bristol, United Kingdom.
J F SwartPaediatric Rheumatology, University Medical Centre Utrecht, Utrecht, Netherlands.
C M HedrichDepartment of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
M W BeresfordDepartment of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
University of Liverpool · GBBristol Royal Hospital for Children · GBLancaster University · GBAarhus University · DKGreat Ormond Street Hospital for Children NHS Foundation Trust · GBNovartis (Switzerland) · CHOur Lady's Hospital · IEOxford University Hospitals NHS Trust · GBRoyal Hospital for Children · GBRoyal National Orthopaedic Hospital · GBUniversity College Hospital · GBUniversity Medical Center Utrecht · NLUniversity of Iowa · USUniversity of Toronto · CA

Funding

Genetic & immunologic etiology of chronic recurrent multifocal osteomyelitis-CRMOR01AR059703 · NIAMS · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G, FERGUSON, POLLY J · 2010 to 2019
$3.5M
Arthritis Research UK 21212Medical Research Council MR/J014079/1Medical Research Council MR/M013510/1NIAMS NIH HHS R01 AR059703
6 · The paper itself

Abstract

introductionChronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregulated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently, treatment is largely based on retrospective observational studies and expert opinion. Treatment usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphosphonates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion.

methodsTwelve international CNO experts were randomly chosen to be invited to a Bayesian prior elicitation meeting.

resultsResults showed that a typical new patient treated with pamidronate would have an 84% chance of improvement in their pain score relative to baseline at 26 weeks and an 83% chance on adalimumab. Experts thought there was a 50% chance that a new typical patient would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26 weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by some margin. However, it is clear that there is considerable uncertainty about the precise relative merits of the two treatments.

conclusionsThe rarity of CNO leads to challenges in conducting randomised controlled trials with sufficient power to provide a definitive outcome. We address this using a Bayesian design, and here describe the process and outcome of the elicitation exercise to establish expert prior opinion. This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases.

Indexed as

AdalimumabBayes TheoremConsensusFemaleHumansMaleOsteomyelitisPain ManagementPamidronateRandomized Controlled Trials as TopicResearch DesignAdalimumabPamidronate

Identifiers

PMID31166977
PMCPMC6550371
OpenAlexW2948773615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.